We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+4.22%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$7.22B
AUM Growth
+$986M
Cap. Flow
+$1.27B
Cap. Flow %
17.6%
Top 10 Hldgs %
44.55%
Holding
109
New
17
Increased
12
Reduced
6
Closed
14

Top Buys

Rank Stock Value
1
CLYM
Climb Bio
CLYM
+$272M
2
CTKB icon
Cytek Biosciences
CTKB
+$226M
3
IVVD icon
Invivyd
IVVD
+$198M
4
ICVX
Icosavax, Inc. Common Stock
ICVX
+$196M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$177M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$112M
2
NVAX icon
Novavax
NVAX
+$102M
3
CRIS icon
Curis
CRIS
+$57.6M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$56.4M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$51.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TIL icon
26
Instil Bio
TIL
$48.3M
$87.1M 1.21%
243,540
– –
CLDX icon
27
Celldex Therapeutics
CLDX
$2.99B
$86.4M 1.2%
+1,600,000
New +$75.1M
KNTE
28
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$82.7M 1.15%
3,593,052
– –
HOWL icon
29
Werewolf Therapeutics
HOWL
$17.2M
$73.6M 1.02%
4,291,881
– –
TNYA icon
30
Tenaya Therapeutics
TNYA
$161M
$73.3M 1.02%
+3,551,508
New +$76.3M
PNT
31
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$68.1M 0.94%
8,856,018
+7,757,700
+706% +$70.8M
GHRS icon
32
GH Research
GHRS
$1.93B
$66.5M 0.92%
3,013,957
+35,002
+1% +$712K
RYTM icon
33
Rhythm Pharmaceuticals
RYTM
$6.81B
$63.6M 0.88%
4,871,067
– –
RCKT icon
34
Rocket Pharmaceuticals
RCKT
$340M
$63M 0.87%
2,107,149
– –
CCCC icon
35
C4 Therapeutics
CCCC
$385M
$61.5M 0.85%
1,377,569
– –
CNTA
36
DELISTED
Centessa Pharmaceuticals
CNTA
$59.7M 0.83%
3,577,094
+2,296,794
+179% +$47.5M
OLMA icon
37
Olema Pharmaceuticals
OLMA
$1B
$59.3M 0.82%
2,150,404
– –
CYT
38
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$58.8M 0.81%
3,350,506
+103,389
+3% +$1.93M
PMVP icon
39
PMV Pharmaceuticals
PMVP
$59.2M
$51M 0.71%
1,710,265
– –
ZGNX
40
DELISTED
Zogenix, Inc.
ZGNX
$50.6M 0.7%
3,333,700
-1,950,276
-37% -$30.5M
DYN icon
41
Dyne Therapeutics
DYN
$4.7B
$45.6M 0.63%
2,805,045
– –
LENZ
42
LENZ Therapeutics
LENZ
$166M
$44.2M 0.61%
385,481
– –
EWTX icon
43
Edgewise Therapeutics
EWTX
$4.13B
$43.4M 0.6%
2,613,623
– –
VERV
44
DELISTED
Verve Therapeutics
VERV
$41.4M 0.57%
880,284
– –
GERN icon
45
Geron
GERN
$828M
$41.3M 0.57%
30,126,299
– –
ACHL
46
DELISTED
Achilles Therapeutics
ACHL
$39.1M 0.54%
5,014,687
– –
RXST icon
47
RxSight
RXST
$249M
$38.7M 0.54%
+3,052,796
New +$42M
WVE icon
48
Wave Life Sciences
WVE
$1.09B
$38.1M 0.53%
7,775,207
– –
KALV
49
DELISTED
KalVista Pharmaceuticals
KALV
$33.7M 0.47%
1,930,322
– –
DSGN icon
50
Design Therapeutics
DSGN
$761M
$32.1M 0.45%
2,186,636
– –
1
2
3 4 5

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, RA Capital Management held 109 positions worth $7.22B, up 16% from $6.23B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RA Capital Management deployed $1.27B of net new capital in Q3 2021, opening 17 new positions and adding to 12 existing holdings. Its largest new stake was Climb Bio: 13,150,849 shares worth $236M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Novavax, an estimated $102M trimmed.

  • RA Capital Management's largest Q3 2021 buy was Climb Bio: 13,150,849 shares worth $236M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q3 2021, an estimated $79.6M increase.
  • RA Capital Management's biggest Q3 2021 reduction was Novavax, cutting an estimated $102M.
  • RA Capital Management fully exited Axsome Therapeutics in Q3 2021, selling an estimated $112M.
  • RA Capital Management's ten largest holdings make up 45% of its $7.22B portfolio in Q3 2021.
  • RA Capital Management opened 17 new positions and closed 14 in Q3 2021.
  • RA Capital Management's portfolio value rose 16% quarter-over-quarter to $7.22B.

Based on RA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.